Severity
Low
FDA Drug recall · Reported July 15, 2020
Failed impurities/degradation products; Presence of an impurity peak that exceeds the approved specification.
VistaPharm, Inc. recalled Nystatin Oral Suspension, USP 100,000 units per mL, Bubblegum Flavored, 16 fl. oz. bottle… - a low-severity action.
Nystatin Oral Suspension, USP 100,000 units per mL, Bubblegum Flavored, 16 fl. oz. bottle… was recalled by VistaPharm, Inc. in July 15, 2020. Reason: Failed impurities/degradation products; Presence of an impurity peak that exceeds the approved specification.. Check the official notice for the remedy. Verify recall #D-1378-2020 with the FDA Drug before acting.
The recall
VistaPharm, Inc. issued this low-severity FDA Drug recall-Failed impurities/degradation products; Presence of an impurity peak that exceeds the approved specification..
Sourced from official FDA Drug enforcement records. Verify recall #D-1378-2020 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1378-2020) was formally reported on July 15, 2020, with the manufacturer initiating the action on June 23, 2020. It is classified under Low severity (Class III), with a current status of Terminated. VistaPharm, Inc. is listed as the recalling firm, operating out of Largo, FL. Federal records list the affected scope as 14,760 bottles.
The documented reason for this recall is: Failed impurities/degradation products; Presence of an impurity peak that exceeds the approved specification. Distribution data in the federal record shows the product reached: United States including Puerto Rico. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 3,731 children & baby products recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
14,760 bottles
Related Recalls
6
0 from same agency
Nystatin Oral Suspension, USP 100,000 units per mL, Bubblegum Flavored, 16 fl. oz. bottle (480 mL), Shake Well Before Using, Rx Only, Manufactured by: VistaPharm, Inc., Largo, FL 33771, NDC 66689-008-16.
Failed impurities/degradation products; Presence of an impurity peak that exceeds the approved specification.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-1378-2020 |
| Date reported | July 15, 2020 |
| Date initiated | June 23, 2020 |
| Recalling firm | VistaPharm, Inc. |
| Firm location | Largo, FL |
| Affected scope | 14,760 bottles |
| Distribution | United States including Puerto Rico |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Xishentang Dongguan Trading Co, Ltd., dba Pretty-Life, of China · 2026-07-02
Diamond Wipes International, Inc. of Chino, California · 2026-07-02
· 2026-07-02
· 2026-07-02
Sanven Technology Ltd., dba Vevor, of Rancho Cucamonga, California · 2026-07-02
Compare this recall with AMASKY Nursing Pillows Recalled Due to Risk of Serious Inju… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported July 15, 2020. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.